Professor Andrew Pollard, the head of the Oxford Vaccine Group and chief investigator into the trial of the vaccine, has become the third patient to receive the new jab.
Report by Thomasl.
Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
